Verona Pharma to initiate second toxicology study of anti-asthma drug

Verona Pharma has reported that the its novel anti-asthmatic compound, RPL554, is entering a second 28-day experimental inhalation toxicology study in another species in order to demonstrate safety, before moving onto the proof of concept clinical trials early 2008.